Patents by Inventor Diane Hatton

Diane Hatton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076626
    Abstract: A directed evolution method for improving performance of a mammalian host cell is provided, as well as host cells generated using the directed evolution method. In one aspect, hydrogen peroxide (H2O2)-evolved host cells are provided. In one aspect, (H2O2)-evolved Chinese hamster ovary (CHO) host cells are provided.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 7, 2024
    Inventors: Rajesh Kumar MISTRY, Emma Jane KELSALL, Si Nga SOU, Suzanne GIBSON, Diane HATTON, Michal JENNS, Katie WILLIS
  • Publication number: 20230340079
    Abstract: The present disclosure relates to nucleic acids that comprise a nucleotide sequence encoding an immunoglobulin heavy chain, wherein the nucleotide sequences of at one or two introns in the immunoglobulin heavy chain are deleted. These nucleic acids are useful for increasing immunoglobulin expression.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 26, 2023
    Inventors: Emma KELSALL, Suzanne GIBSON, Diane HATTON
  • Patent number: 11441197
    Abstract: As demonstrated herein, when composite transcription factor binding sites do not function synergistically, mammalian promoters can be constructed according to simple design rules. Host-cell transcriptional machinery components were analyzed in silico to identify transcription factors with desired expression dynamics. Cognate binding sites were then comprehensively tested in homotypic and heterotypic architectures to assess modularity and determine the transcriptional activity exhibited by a single copy of each site. When elements were specifically selected to prevent combinatorial interactions, heterotypic promoter activities could be accurately modeled simply as a function of constituent binding site copy numbers. As binding site order, spacing, and orientation had minimal effect on promoter activity, blocks could be optimally combined and arranged in silico according to context-specific design-criteria.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 13, 2022
    Assignee: MedImmune Limited
    Inventors: Adam J. Brown, David C. James, Suzanne J. Gibson, Diane Hatton
  • Publication number: 20210147951
    Abstract: Simplified models of gene regulation are a fundamental requirement for mammalian synthetic biology. However, at the transcriptional level this has been impeded by the complex design rules governing promoter activity dynamics, preventing de novo-design of regulatory elements with user-defined functionalities. As demonstrated herein, when composite transcription factor binding sites do not function synergistically, mammalian promoters can be constructed according to simple design rules. Host-cell transcriptional machinery components were analyzed in silico to identify transcription factors with desired expression dynamics. Cognate binding sites were then comprehensively tested in homotypic and heterotypic architectures to assess modularity and determine the transcriptional activity exhibited by a single copy of each site.
    Type: Application
    Filed: April 19, 2018
    Publication date: May 20, 2021
    Inventors: ADAM J. BROWN, DAVID C. JAMES, SUZANNE J. GIBSON, DIANE HATTON
  • Patent number: 10618952
    Abstract: We discovered that recombinant antibody light chains having a murine secretory leader sequence and an SYE motif at the N-terminus are truncated during post-translational processing. This disclosure provides two protein engineering solutions: to alter the SYE amino acid sequence of the Lc N-terminus to other alternatives; or to change the secretory leader peptide sequence. We have shown that both of these solutions are effective for preventing N-terminal light chain truncation.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: April 14, 2020
    Assignee: MedImmune Limited
    Inventors: Nicholas J. Bond, Suzanne J. Gibson, Diane Hatton, Daniel R. Higazi, Sarah Milne, Mariana Alessia Sheriff
  • Publication number: 20180251525
    Abstract: We discovered that recombinant antibody light chains having a murine secretory leader sequence and an SYE motif at the N-terminus are truncated during post-translational processing. This disclosure provides two protein engineering solutions: to alter the SYE amino acid sequence of the Lc N-terminus to other alternatives; or to change the secretory leader peptide sequence. We have shown that both of these solutions are effective for preventing N-terminal light chain truncation.
    Type: Application
    Filed: October 28, 2016
    Publication date: September 6, 2018
    Inventors: Nicholas J. Bond, Suzanne J. Gibson, Diane Hatton, Daniel R. Higazi, Sarah Milne, Mariana Alessia Sheriff
  • Publication number: 20160272706
    Abstract: Novel anti-IL-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce IL-13 activity and to treat IL-13-associated diseases and conditions are further provided.
    Type: Application
    Filed: January 11, 2016
    Publication date: September 22, 2016
    Inventors: Sara Carmen, David Lowe, Matthew J. Gardener, D. Gareth Rees, Ian Strickland, Richard D. May, Tarik Senussi, Bojana Popovic, Jianqing Xu, Suzanne J. Gibson, Diane Hatton
  • Patent number: 9068198
    Abstract: The present invention is related to a Chinese hamster ovary cell line as deposited with the European Collection of Cell Cultures (ECACC) under accession number 10090201; use of the cell line for the production of a recombinant polypeptide; a kit comprising the cell line; and methods for the production of recombinant polypeptide.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: June 30, 2015
    Assignee: MedImmune Limited
    Inventors: Diane Hatton, Ray Field, Wyn Forrest-Owen, Victoria Richardson
  • Patent number: 8822214
    Abstract: This invention relates to the transient expression of heterologous polypeptides in mammalian cell lines. Specifically it relates to an expression-enhanced cell line derived from a parent cell line, the expression-enhanced cell line comprising nucleic acid encoding Epstein-Barr Virus Nuclear Antigen 1 or a functional derivative, analogue, or variant thereof; and further comprising: (a) a nucleic acid encoding an exogenous glutamine synthetase; (b) a nucleic acid encoding an endogenous glutamine synthetase, wherein the endogenous glutamine is arranged to have enhanced enzymatic activity and/or enhanced expression relative to the parent cell line under comparable conditions; or (c) both (a) and (b).
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: September 2, 2014
    Assignee: MedImmune Limited
    Inventors: Olalekan Daramola, Gregory Dean, Diane Hatton, Jessica Stevenson
  • Publication number: 20140011237
    Abstract: The present invention is related to a Chinese hamster ovary cell line as deposited with the European Collection of Cell Cultures (ECACC) under accession number 10090201; use of the cell line for the production of a recombinant polypeptide; a kit comprising the cell line; and methods for the production of recombinant polypeptide.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 9, 2014
    Applicant: MedImmune Limited
    Inventors: Diane Hatton, Ray Field, Wyn Forrest-Owen, Victoria Richardson
  • Publication number: 20120231500
    Abstract: This invention relates to the transient expression of heterologous polypeptides in mammalian cell lines. Specifically it relates to an expression-enhanced cell line derived from a parent cell line, the expression-enhanced cell line comprising nucleic acid encoding Epstein-Barr Virus Nuclear Antigen 1 or a functional derivative, analogue, or variant thereof; and further comprising: (a) a nucleic acid encoding an exogenous glutamine synthetase; (b) a nucleic acid encoding an endogenous glutamine synthetase, wherein the endogenous glutamine is arranged to have enhanced enzymatic activity and/or enhanced expression relative to the parent cell line under comparable conditions; or (c) both (a) and (b).
    Type: Application
    Filed: September 15, 2010
    Publication date: September 13, 2012
    Applicant: Medlmmune Limited
    Inventors: Olalekan Daramola, Gregory Dean, Diane Hatton, Jessica Stevenson